Publication | Closed Access

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Surgical OncologyHer2-positive Metastatic GastricPlacebo-controlled Phase 3Gastrointestinal OncologyMedicineGastroenterologyPathologyCancer TreatmentOncologyRadiation OncologyGastro-oesophageal Junction Cancer